Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia

JOURNAL ARTICLE published 15 July 2013 in Cancer

Authors: Hagop M. Kantarjian | Giovanni Martinelli | Elias J. Jabbour | Alfonso Quintás‐Cardama | Kiyoshi Ando | Jacques‐Olivier Bay | Andrew Wei | Stefanie Gröpper | Cristina Papayannidis | Kate Owen | Laura Pike | Nicola Schmitt | Paul K. Stockman | Aristoteles Giagounidis | SPARK‐AML1 Investigators